RSS Content

Zomedica to Present at 2018 Disruptive Growth & Healthcare Conference

ANN ARBOR, Mich., May 07, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it will present at the 2018 Disruptive Growth & Healthcare Conference on Tuesday, May 8, 2018 at 11:10 a.m. EDT in New York, NY.

Chief Executive Officer Gerald Solensky, Jr. will provide an overview of Zomedica’s business during his live presentation and will be available to participate in one-on-one meetings with investors registered to attend the conference.

Solensky is also part of a panel discussion on “Disrupting Crop Productivity/Sustainability, Farming & Animal Health” at 8:15 a.m. EDT.

2018 Disruptive Growth & Healthcare Conference
Date: Tuesday, May 8, 2018
Time: Panel Discussion, 8:15 a.m. EDT and Company Overview, 11:10 a.m. EDT
Location: Reed Smith LLP, 599 Lexington Avenue, New York, NY 10022

Investors and other interested parties will be able to access a live webcast of the company presentation by visiting Zomedica’s website at http://investors.zomedica.com. A replay of the webcast will be accessible on the Zomedica website for 90 days following the event.

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Investor Relations Contacts
Shameze Rampertab, CPA, CA
srampertab@zomedica.com
+1 647.283.3630

PCG Advisory Group
Kirin Smith, COO
ksmith@pcgadvisory.com
+1 646.863.6519
www.pcgadvisory.com

Media Contact
Andrea Eberle
aeberle@zomedica.com
+1 734.369.2555

Primary Logo

Zomedica Pharmaceuticals Corp.